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Abstract
Extended-spectrum β-lactamases, carbapenemases, 16S rRNA methylases conferring pan-drug aminoglycoside resistance and colistin
resistance were investigated among Gram-negative bacteria recovered from clinical samples (infections) from 200 individuals hospitalized
at the Khyber Teaching Hospital of Peshawar, north Pakistan, from December 2017 to March 2018. Out of 65 isolates recovered, 19%
were carbapenem resistant and 16% carried a blaNDM-1 gene, conﬁrming the widespread distribution of NDM producers in this country.
The association of the NDM carbapenem-resistance determinant, together with the extended-spectrum β-lactamase CTX-M-15 and 16S
rRNA methylases, was frequent, explaining the multidrug-resistance pattern observed. All isolates remained susceptible to colistin.
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Introduction
The increasing occurrence of resistance to carbapenems is a
major issue for global public health. Resistance to carbapenems
is often mediated by carbapenemases, with NDM-1 (New Delhi
metallo-β-lactamase) being one of the most commonly identi-
ﬁed carbapenemases worldwide, its main reservoir corre-
sponding to the Indian subcontinent [1]. Accordingly, several
studies reported a high occurrence of NDM-1 producers in
India and Pakistan [2,3]. Most of the carbapenemase producers
are co-resistant to other antibiotic families, so it is interesting
to obtain further characterization about those co-resistance
markers [4]. Our aim was to characterize the carbapene-
mases, extended-spectrum β-lactamases (ESBLs), 16S rRNA
methylases conferring pan-aminoglycoside resistance, and
colistin resistance (plasmid-mediated mcr genes) from a series
of clinical isolates obtained in acute-care facilities from Pesha-
war, Pakistan.
Materials and methods
Bacterial isolates
A total of 200 samples were collected from 200 individuals
between December 2017 and March 2018 at the Khyber
Teaching Hospital of Peshawar, north Pakistan. Those samples
included urine, blood, pus and broncheal lavage specimens.
Samples were plated on URIselect-4™ medium (Bio-Rad,
Cressier, Switzerland) and identiﬁcation was performed using
the API-20E system (bioMérieux, La Balme-les-Grottes,
France). Antimicrobial susceptibility testing was performed
using the disc diffusion method and interpreted according to
the CLSI recommendations [5], except for colistin. Resistance
to colistin was evaluated ﬁrst by using the Rapid Polymyxin test
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[6], and then by determination of MIC values of colistin by
broth microdilution, as recommended by European Committee
on Antimicrobial Susceptibility Testing (EUCAST) (www.
eucast.org). Carbapenemase and ESBL activities were detec-
ted using the Carba NP test [7] and the ESBL NP test [8],
respectively.
Molecular analysis
A series of acquired resistance genes were searched by PCR,
including those encoding ESBLs (blaTEM-, blaSHV- and blaCTX-M-
like genes), carbapenemases (blaKPC, blaNDM, blaVIM, blaIMP,
blaOXA-48, blaOXA-181), 16S rRNA methylases genes (armA, rmtA
to rmtH and npmA), and mcr-like genes (mcr-1 to mcr-8) [9–14].
The obtained amplicons were sent for sequencing (Micro-
synth®, Balgach, Switzerland).
Clonal diversity
Clonal relationship of the isolates was evaluated by pulsed-ﬁeld
gel electrophoresis (PFGE) [15]. Total DNA from Escherichia
coli, Klebsiella pneumoniae and Enterobacter spp. were digested
using the XbaI enzyme (New England Biolabs, Ipswich, MA,
USA). The generated fragments were separated by PFGE using
a CHEF-DR III System (Bio-Rad) creating a unique PFGE proﬁle
for each clonal strain. Multilocus sequencing typing was per-
formed for pan-drug aminoglycoside-resistant strains belonging
to the species E. coli (strain no. 31) and K. pneumoniae (strain
no. 62) [16]. Sequence types (STs) were investigated using the
online databases (http://genomicepidemiology.org/).
Results
A total of 65 Gram-negative bacteria were recovered including
46 E. coli, 10 Enterobacter spp. (9 Enterobacter cloacae, 1
Enterobacter sakazakii), 6 K. pneumoniae, 2 Alcaligenes faecalis
and 1 Citrobacter freundii.
Thirty-eight of the 65 Gram-negative bacteria produced a
carbapenemase, as assessed by the results of the Rapid Carba
NP test, whereas 32 of those 65 isolates produced an ESBL
according to the results of the ESBL NP test. Among the 46
E. coli isolates, 12 produced NDM-1, 5 co-produced NDM-1
and CTX-M-15, 2 co-produced NDM-1 and OXA-181, 2
isolates co-producing OXA-181 and CTX-M-15, a single
isolate producing OXA-48. Twelve E. coli isolates produced
CTX-M-15 without any carbapenemase associated. A single
blaNDM-1-positive E. coli isolate produced the 16S rRNA
methylase RmtB.
Among the six K. pneumoniae isolates, one isolate co-
produced NDM-1 and CTX-M-15, another co-produced
NDM-1, OXA-181 and CTX-M-15, and a single isolate co-
produced NDM-1, OXA-232 and CTX-M-15 together with
the 16S rRNA methylase RmtB (see Table 1).
The ten Enterobacter spp. isolates (nine Enterobacter
cloacae, one Enterobacter sakazakii) co-produced NDM-1 and
CTX-M-15.
Two Alcaligenes faecalis isolates were identiﬁed, both pro-
ducing a carbapenemase VIM-4.
The single C. freundii isolate did not produce any carbapen-
emase but was positive for CTX-M-15. None of the isolates
was resistant to colistin. PFGE analysis showed a very high
clonal diversity for all those isolates producing a carbapenem-
ase, except among Enterobacter spp. with a single clone being
identiﬁed among six patients (EC-1) that may have resulted
from an outbreak.
By using MLST, we showed that the blaNDM-1 and rmtB-
positive E. coli clone belonged to ST215 (strain no. 31) and that
the multidrug-resistant K. pneumoniae isolate belonged to
ST231 (strain no. 62).
Discussion
Here we evaluated the occurrence of multidrug resistance from
infecting strains (not colonizers) from individuals hospitalized at
the Khyber Teaching Hospital, Peshawar, north Pakistan from
November 2017 to March 2018. A rate of 19% of carbapenem-
resistant Enterobacteriaceae (38/200) was identiﬁed, among
which 16% harboured the blaNDM-1 gene. This overall rate of
16% of NDM producers is in accordance with the estimated
rate of NDM producers in Enterobacteriaceae in Pakistan
(8.7%–18.5%). Actually, 18.5% stool samples were found to
contain blaNDM-1-positive strains (mostly E. coli and Enterobacter
cloacae) in military hospitals of Rawalpindi (Combined Military
Hospitals and Military Hospital at Rawalpindi) [17], 8.7% of the
isolates were NDM-1 positive (K. pneumoniae, E. coli, Pseudo-
monas aeruginosa) from two tertiary-care hospitals (Pakistan
Institute of Medical Science, Islamabad and Mayo Hospital,
Lahore) [18] and 14.6% of the strains carried blaNDM-1 (E. coli,
Enterobacter cloacae, Pseudomonas putida and K. pneumoniae
from three children’s hospitals (The Children’s Hospital,
Islamabad, The Children’s Hospital Multan and Nishtar Hospi-
tal, Multan) [19].
Interestingly, some strains were found to harbour two un-
related carbapenemase genes (blaNDM-1 and blaOXA-181), as
observed previously in Singapore [20], Nigeria [21] and
Romania [22].
In our study, co-resistance to multiple antibiotics was
commonly observed among those carbapenem-resistant iso-
lates, with 60% of them harbouring at least two other resis-
tance genes (ESBL, or 16S rRNA methylase gene). A single
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K. pneumoniae isolate carried two carbapenemase genes,
namely blaNDM-1 and blaOXA-232, along with the ESBL-encoding
gene blaCTX-M-15 and the 16S rRNA methylase gene rmtB. That
isolate was an ST231 clone, already described in South-East
Asia [23,24] and Switzerland [25], and associated with
OXA-232.
Among the 16S rRNA methylase genes, the methylase gene
rmtB, rather than rmtF, was mostly identiﬁed here, which is not
surprising owing to the spread of rmtB-positive strains in
Pakistan [26]. Our study showed the frequent identiﬁcation of
the ESBL CTX-M-15 among those multidrug-resistant bacteria.
It is possible that the spread of CTX-M-15 that is observed
worldwide originated from the Indian subcontinent because we
identiﬁed the ﬁrst CTX-15 producers from India in 2001 [27].
Our study conﬁrms the frequent association of those three
important resistance markers that are NDM, ESBL of the CTX-
TABLE 1. Information and genetic features of samples isolated in Peshawar teaching hospital, Pakistan
Patient/strain
no.
Site of
isolation Residence Treatment Strains Carbapenemase ESBL
16S RNA
methyltransferase Clonality
1 Pus Peshawar Ciproﬂoxacin Alcaligenes faecalis VIM-4 None None None
2 Urine Mardan Oﬂoxine Alcaligenes faecalis VIM-4 None None None
3 Urine Batkhela Unknown Citrobacter freundii None CTX-M-15 None EsC-7
4 Pus Peshawar Ciproﬂoxacin Enterobacter cloacae NDM-1 None None EC-1
5 Urine Peshawar Unknown Enterobacter cloacae NDM-1 CTX-M-15 None EC-1
6 Urine Kohat Unknown Enterobacter cloacae NDM-1 CTX-M-15 None EC-1
7 Blood Unknown Ceﬁxime Enterobacter cloacae NDM-1 CTX-M-15 None EC-1
8 Urine Mardan Oﬂoxine Enterobacter cloacae NDM-1 CTX-M-15 None EC-1
9 Urine Afghanistan Unknown Enterobacter cloacae NDM-1 CTX-M-15 None EC-1
10 Urine Afghanistan Unknown Enterobacter cloacae NDM-1 CTX-M-15 None EC-1
11 Urine Peshawar Levoﬂoxacin Enterobacter cloacae NDM-1 CTX-M-15 None None
12 Urine Peshawar Levoﬂoxacin Enterobacter cloacae NDM-1 CTX-M-15 None None
13 Urine Peshawar Unknown Enterobacter sakazakii NDM-1 CTX-M-15 None None
14 Fluid Peshawar Ciproﬂoxacin Escherichia coli NDM-1 None None None
15 Pus Charsada Ciproﬂoxacin Escherichia coli NDM-1 None None None
16 Pus Dir Amoxicillin Escherichia coli NDM-1 None None None
17 Pus Peshawar Levoﬂoxacin Escherichia coli NDM-1 None None None
18 Pus Peshawar Levoﬂoxacin Escherichia coli NDM-1 None None None
19 Pus Peshawar Unknown Escherichia coli NDM-1 None None None
20 Pus Peshawar Unknown Escherichia coli NDM-1 None None None
21 Urine Peshawar Ceftriaxone Escherichia coli NDM-1 None None None
22 Urine Peshawar Ciproﬂoxacin Escherichia coli NDM-1 None None None
23 Urine Peshawar Unknown Escherichia coli NDM-1 None None None
24 Urine Peshawar Unknown Escherichia coli NDM-1 None None None
25 Unknown Peshawar Ceﬁxime Escherichia coli NDM-1 None None None
26 Blood Mardan Unknown Escherichia coli NDM-1 CTX-M-15 None None
27 Blood Peshawar Unknown Escherichia coli NDM-1 CTX-M-15 None EsC-15
28 Urine Peshawar Unknown Escherichia coli NDM-1 CTX-M-15 None None
29 Urine Peshawar Unknown Escherichia coli NDM-1 CTX-M-15 None None
30 Urine Peshawar Unknown Escherichia coli NDM-1 CTX-M-15 None None
31 Unknown Unknown Unknown Escherichia coli NDM-1 None rmtB ST 215
32 Urine Peshawar Ciproﬂoxacin Escherichia coli NDM-1; OXA-181 None None EsC-10
33 Urine Peshawar Unknown Escherichia coli NDM-1; OXA-181 None None None
34 Urine Peshawar Ciproﬂoxacin Escherichia coli OXA-48 None None EsC-1
35 Blood Peshawar Ciproﬂoxacin Escherichia coli OXA-181 CTX-M-15 None EsC-5
36 Blood Peshawar Unknown Escherichia coli OXA-181 CTX-M-15 None EsC-1
37 Blood Kohat Unknown Escherichia coli None CTX-M-15 None EsC-14
38 Pus Dir Unknown Escherichia coli None CTX-M-15 None EsC-2
39 Pus Peshawar Oﬂoxine Escherichia coli None CTX-M-15 None EsC-2
40 Urine Peshawar Amoxicillin-Clavulanate Escherichia coli None CTX-M-15 None EsC-2
41 Urine Peshawar Levoﬂoxacin Escherichia coli None CTX-M-15 None EsC-2
42 Bronchial lavage Peshawar Levoﬂoxacin Escherichia coli None CTX-M-15 None EsC-3
43 Pus Peshawar Ceﬁxime Escherichia coli None CTX-M-15 None EsC-3
44 Urine Peshawar Unknown Escherichia coli None CTX-M-15 None EsC-3
45 Urine Kohat Unknown Escherichia coli None CTX-M-15 None EsC-3
46 Urine Peshawar Ciproﬂoxacin Escherichia coli None CTX-M-15 None EsC-9
47 Urine Peshawar Levoﬂoxacin Escherichia coli None CTX-M-15 None EsC-12
48 Urine Afghanistan Levoﬂoxacin Escherichia coli None CTX-M-15 None None
49 Blood Peshawar Ceﬁxime Escherichia coli None None None EsC-16
50 Blood Unknown Ceﬁxime Escherichia coli None None None EsC-13
51 Pus Afghanistan Unknown Escherichia coli None None None EsC-11
52 Pus Charsada Ciproﬂoxacin Escherichia coli None None None None
53 Pus Peshawar Ciproﬂoxacin Escherichia coli None None None None
54 Pus Peshawar Linezolid Escherichia coli None None None EsC-18
55 Urine Afghanistan Unknown Escherichia coli None None None EsC-17
56 Urine Peshawar Ceﬁxime Escherichia coli None None None EsC-4
57 Urine Peshawar Unknown Escherichia coli None None None EsC-4
58 Urine Peshawar Unknown Escherichia coli None None None EsC-6
59 Urine Peshawar Unknown Escherichia coli None None None EsC-8
60 Blood Peshawar Ceﬁxime Klebsiella pneumoniae NDM-1 CTX-M-15 None KP-1
61 Pus Dir Amoxicillin Klebsiella pneumoniae NDM-1; OXA-181 None None KP-1
62 Blood Mardan Unknown Klebsiella pneumoniae NDM-1; OXA-232 CTX-M-15 rmtB ST 231
63 Pus Peshawar Ciproﬂoxacin Klebsiella pneumoniae None None None KP-2
64 Urine Noweshehra Ciproﬂoxacin Klebsiella pneumoniae None None None KP-2
65 Unknown Afghanistan Levoﬂoxacin Klebsiella pneumoniae None None None None
Abbreviations: EC, Enterobacter cloacae clone X; ESBL, extended spectrum β-lactamase; EsC, Escherichia coli clone X; KP, Klebsiella pneumoniae clone X; ST, sequence type.
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M-15 type and 16S rRNA methylases as a source of multidrug
resistance. This combination complicates the treatment of
infected patients.
We also identiﬁed two A. faecalis isolates producing a same
VIM-4 metallo-β-lactamase. Occurrence of carbapenemase
production in that bacterial species is rare. Only a single case of
A. faecalis carrying blaVIM-4 has been described in Gaza, Palestine
[28]. Further work may identify the genetic basis of such
acquisition of carbapenemase. Other reports about ESBL in
clinical isolates of Alcaligenes species have been described in
Malaysia [29], France [30] and Italy [31].
Finally, no resistance to colistin was observed whereas MCR-
1-mediated colistin resistance isolates was observed recovered
from E. coli in animals [32,33] and from a single patient [34] in
Pakistan. Lack of colistin resistance among those multidrug-
resistant isolates is good news as it would indicate the avail-
ability to use that drug for treating infected patients in this
country.
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